Peter Kubiak

535 total citations
14 papers, 277 citations indexed

About

Peter Kubiak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Kubiak has authored 14 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Peter Kubiak's work include Cancer Immunotherapy and Biomarkers (7 papers), Renal cell carcinoma treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Peter Kubiak is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Renal cell carcinoma treatment (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). Peter Kubiak collaborates with scholars based in United States, United Kingdom and Spain. Peter Kubiak's co-authors include Carlos Gomez‐Roca, Razi Ghori, Hyun Cheol Chung, Kevin Norwood, Hélène Senellart, Sanjeev Gill, Juanita Lopez, Eduardo Yáñez, Fan Jin and Mark Doherty and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Peter Kubiak

13 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Kubiak United States 8 218 116 105 59 31 14 277
М. Yu. Fedyanin Russia 8 198 0.9× 83 0.7× 104 1.0× 59 1.0× 27 0.9× 107 308
И. А. Покатаев Russia 7 141 0.6× 78 0.7× 101 1.0× 25 0.4× 18 0.6× 86 246
L. V. Manzyuk Russia 5 193 0.9× 110 0.9× 108 1.0× 68 1.2× 44 1.4× 14 306
Ji Hyun Park South Korea 8 123 0.6× 60 0.5× 146 1.4× 94 1.6× 15 0.5× 22 307
Quanren Wang China 1 245 1.1× 61 0.5× 148 1.4× 82 1.4× 67 2.2× 2 368
Masashi Fujii Japan 11 221 1.0× 81 0.7× 144 1.4× 51 0.9× 13 0.4× 45 297
Ning‐Fu Peng China 12 150 0.7× 65 0.6× 71 0.7× 30 0.5× 21 0.7× 20 356
B. Killing Germany 7 288 1.3× 57 0.5× 141 1.3× 51 0.9× 20 0.6× 9 329
Ken Kato Japan 12 187 0.9× 133 1.1× 160 1.5× 30 0.5× 13 0.4× 42 341
Zhongmin Maxwell Wang Australia 10 210 1.0× 31 0.3× 70 0.7× 31 0.5× 117 3.8× 17 330

Countries citing papers authored by Peter Kubiak

Since Specialization
Citations

This map shows the geographic impact of Peter Kubiak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kubiak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kubiak more than expected).

Fields of papers citing papers by Peter Kubiak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kubiak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kubiak. The network helps show where Peter Kubiak may publish in the future.

Co-authorship network of co-authors of Peter Kubiak

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kubiak. A scholar is included among the top collaborators of Peter Kubiak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kubiak. Peter Kubiak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Chung, Hyun Cheol, Luis J. Villanueva-Rivera, Donna M. Graham, et al.. (2021). P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort. Annals of Oncology. 32. S146–S146. 2 indexed citations
3.
Chung, Hyun Cheol, Zarnie Lwin, Carlos Gomez‐Roca, et al.. (2021). LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.. Journal of Clinical Oncology. 39(15_suppl). 4030–4030. 4 indexed citations
4.
Villanueva-Rivera, Luis J., Zarnie Lwin, Hyun Cheol Chung, et al.. (2021). Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.. Journal of Clinical Oncology. 39(3_suppl). 321–321. 49 indexed citations
5.
Gomez‐Roca, Carlos, Eduardo Yáñez, Seock‐Ah Im, et al.. (2021). LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.. Journal of Clinical Oncology. 39(3_suppl). 94–94. 53 indexed citations
6.
Villanueva-Rivera, Luis J., Zarnie Lwin, Hyun Cheol Chung, et al.. (2021). Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.. Journal of Clinical Oncology. 39(15_suppl). 4080–4080. 21 indexed citations
7.
Gomez‐Roca, Carlos, Eduardo Yáñez, Seock‐Ah Im, et al.. (2021). LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.. Journal of Clinical Oncology. 39(15_suppl). 3564–3564. 17 indexed citations
8.
Chung, Hyun Cheol, Zarnie Lwin, Carlos Gomez‐Roca, et al.. (2021). LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.. Journal of Clinical Oncology. 39(3_suppl). 230–230. 15 indexed citations
9.
Lwin, Zarnie, Carlos Gomez‐Roca, Esma Saâda-Bouzid, et al.. (2020). LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours. Annals of Oncology. 31. S1170–S1170. 59 indexed citations
10.
Lee, Chi‐Hang, Yusuke Adachi, Hiroki Ikezawa, et al.. (2020). 719P Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC). Annals of Oncology. 31. S564–S565. 2 indexed citations
11.
Lee, Chung‐Han, Amishi Y. Shah, James J. Hsieh, et al.. (2020). Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology. 38(15_suppl). 5008–5008. 31 indexed citations
12.
13.
González-Martı́n, Antonio, Hyun Cheol Chung, Esma Saâda-Bouzid, et al.. (2020). 2 Efficacy and safety of lenvatinib plus pembrolizumab in patients with previously treated ovarian cancer in the multicohort phase 2 LEAP-005 study. A1.2–A2. 3 indexed citations
14.
Mistry, Bipin, Mark M. Jones, Peter Kubiak, et al.. (2011). A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),. Blood. 118(21). 3801–3801. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by М. Yu. Fedyanin Breakdown of academic impact, for papers by И. А. Покатаев Breakdown of academic impact, for papers by L. V. Manzyuk Breakdown of academic impact, for papers by Ji Hyun Park Breakdown of academic impact, for papers by Quanren Wang Breakdown of academic impact, for papers by Masashi Fujii Breakdown of academic impact, for papers by Ning‐Fu Peng Breakdown of academic impact, for papers by B. Killing Breakdown of academic impact, for papers by Ken Kato Breakdown of academic impact, for papers by Zhongmin Maxwell Wang
Rankless by CCL
2026